Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics Announces Exploration of Strategic Alternatives

GlobeNewswire July 11, 2024

Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica

GlobeNewswire June 12, 2024

Cara Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire May 13, 2024

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

GlobeNewswire May 6, 2024

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024

GlobeNewswire March 7, 2024

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire March 4, 2024

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

GlobeNewswire February 12, 2024

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026

GlobeNewswire January 22, 2024

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

GlobeNewswire December 18, 2023

Cara Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire November 13, 2023

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty

GlobeNewswire November 2, 2023

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023

GlobeNewswire October 23, 2023

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

GlobeNewswire September 25, 2023

Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Cara Therapeutics Reports Second Quarter 2023 Financial Results

GlobeNewswire August 7, 2023

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

GlobeNewswire August 3, 2023

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire August 2, 2023

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

GlobeNewswire July 24, 2023

Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire June 2, 2023